TNSN06133A1 - Immunoglobulin variants and uses thereof - Google Patents

Immunoglobulin variants and uses thereof

Info

Publication number
TNSN06133A1
TNSN06133A1 TNP2006000133A TNSN06133A TNSN06133A1 TN SN06133 A1 TNSN06133 A1 TN SN06133A1 TN P2006000133 A TNP2006000133 A TN P2006000133A TN SN06133 A TNSN06133 A TN SN06133A TN SN06133 A1 TNSN06133 A1 TN SN06133A1
Authority
TN
Tunisia
Prior art keywords
immunoglobulin variants
immunoglobulin
variants
antibodies
treatment
Prior art date
Application number
TNP2006000133A
Other languages
English (en)
Inventor
C Chan Andrew
W Crowley Craig
B Lowman Henry
R Nakamura Gerald
G Presta Leonard
W Adams Camellia
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36166967&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN06133(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2003/040426 external-priority patent/WO2004056312A2/fr
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of TNSN06133A1 publication Critical patent/TNSN06133A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

THE INVENTION PROVIDES HUMANIZED AND CHIMERIC ANTI-CD20 ANTIBODIES FOR TREATMENT OF CD20 POSITIVE MALIGNANCIES AND AUTOIMMUNE DISEASES.
TNP2006000133A 2002-12-16 2006-05-10 Immunoglobulin variants and uses thereof TNSN06133A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43411502P 2002-12-16 2002-12-16
PCT/US2003/040426 WO2004056312A2 (fr) 2002-12-16 2003-12-16 Variants d'immunoglobuline et utilisations

Publications (1)

Publication Number Publication Date
TNSN06133A1 true TNSN06133A1 (en) 2007-11-15

Family

ID=36166967

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000133A TNSN06133A1 (en) 2002-12-16 2006-05-10 Immunoglobulin variants and uses thereof

Country Status (6)

Country Link
CN (6) CN1748143A (fr)
CA (1) CA2835591A1 (fr)
CL (1) CL2003002639A1 (fr)
NO (1) NO338313B1 (fr)
TN (1) TNSN06133A1 (fr)
ZA (1) ZA200504221B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2557587T3 (es) 2004-12-28 2016-01-27 Innate Pharma Anticuerpos monoclonales contra NKG2A
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
US8796427B2 (en) * 2008-01-24 2014-08-05 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
CN102439163A (zh) * 2009-02-16 2012-05-02 拜奥雷克斯治疗公司 人源化抗cd20抗体及使用方法
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
CN102190728B (zh) 2010-03-17 2014-07-02 永卓博济(上海)生物医药技术有限公司 一种人源化抗cd20单克隆抗体
DK3375284T3 (da) * 2011-02-15 2023-06-12 Univ Yale Humaniserede M-CSF-mus og anvendelser deraf
CN103635487B (zh) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
SI2771364T1 (sl) * 2011-10-27 2019-10-30 Genmab As Produkcija heterodimernih proteinov
CA2853138A1 (fr) 2011-12-05 2013-06-13 Immunomedics, Inc. Utilisation therapeutique d'anticorps anti-cd22 pour induire une trogocytose
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN103936855B (zh) * 2014-03-27 2016-05-04 合肥泰瑞生物技术有限公司 抗cd20抗原的抗体l4h5及其应用
CN103936858B (zh) * 2014-03-27 2016-05-04 安徽大学 抗cd20抗原的抗体l5h6及其应用
CN103880957B (zh) * 2014-03-27 2016-01-20 安徽大学 抗cd20抗原的抗体l1h1及其应用
CN103897059B (zh) * 2014-03-27 2016-03-23 中国人民解放军军事医学科学院生物工程研究所 抗cd20抗原的抗体l5h7及其应用
CN103880958B (zh) * 2014-03-27 2016-01-20 安徽大学 抗cd20抗原的抗体l4h6及其应用
JP6752221B2 (ja) 2015-04-13 2020-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｓｉｒｐａ−ｉｌ１５ノックインマウス及びその使用方法
KR20190038613A (ko) * 2016-08-11 2019-04-08 더 잭슨 래보라토리 유전자 변형된 면역결핍 비-인간 동물에서의 개선된 인간 적혈구 생존에 관한 방법 및 조성물
CN106872713A (zh) * 2016-12-27 2017-06-20 许洋 一种微量蛋白质原位检测的免疫质谱试剂盒及制备方法
CN108531561A (zh) * 2017-03-01 2018-09-14 云南序源生物技术开发有限公司 一种快速检测用于鉴定y染色体单倍型谱系的snp特征位点的试剂盒及方法
CN111705084B (zh) * 2020-08-18 2020-12-08 江苏集萃药康生物科技有限公司 一种稳定表达荧光素酶及人cd20敲除鼠cd20的小鼠b细胞淋巴瘤细胞系构建方法
CN114990128A (zh) * 2021-06-16 2022-09-02 百奥赛图(北京)医药科技股份有限公司 Cd20基因人源化非人动物的构建方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
HU228180B1 (hu) * 1998-08-11 2013-01-28 Biogen Idec Inc Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
CA2422076A1 (fr) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Polytherapie pour le traitement de maladies auto-immunes utilisant une combinaison d'anticorps d'immunoregulation/de depletion de cellules b
AU2002213357A1 (en) * 2000-10-20 2002-05-06 Idec Pharmaceuticals Corporation Variant igg3 rituxan r and therapeutic use thereof

Also Published As

Publication number Publication date
CN1748143A (zh) 2006-03-15
CN101418044A (zh) 2009-04-29
CL2003002639A1 (es) 2005-04-08
NO20150245L (no) 2005-08-31
ZA200504221B (en) 2006-08-30
CN1747969A (zh) 2006-03-15
CN101418045A (zh) 2009-04-29
NO338313B1 (no) 2016-08-08
CN100460421C (zh) 2009-02-11
CN101418043A (zh) 2009-04-29
CN101418044B (zh) 2014-03-12
CA2835591A1 (fr) 2004-07-08
CN1751236A (zh) 2006-03-22

Similar Documents

Publication Publication Date Title
TW200501982A (en) Immunoglobulin variants and uses thereof
TNSN06133A1 (en) Immunoglobulin variants and uses thereof
TW200639182A (en) Antibody variants and uses thereof
MY176959A (en) Humanized antibodies that recognize beta amyloid peptide
HK1221473A1 (zh) 人源化的抗β 拮抗劑及其應用
MY139983A (en) Humanized antibodies that recognize beta amyloid peptide
WO2003068821A3 (fr) Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation
MXPA03005048A (es) Anticuerpos humanizados que reconocen el peptido amiloideo beta.
EP1613347A4 (fr) Anticorps humanises reconnaissant le peptide beta-amyloide
EP1135415A4 (fr) Anticorps anti-interferon gamma humanises
TN2009000104A1 (en) Therapeutic compositions for boosting the effect of antibody therapy against the epidermal growth factor receptor
ECSP066631A (es) Variantes de inmunoglobulinas y uso de las mismas
MY135982A (en) Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-cd20 antibody